Theravance Biopharma (TBPH) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.09 per share when it actually produced a loss of $0.13, delivering a surprise of -44.44%.Over the last four quarters, the ...